Observational cohort for patients with Idiopathic Interstitial Pneumopathy
Idiopathic Interstitial Pneumopathy : Genetic and Environmental Determinants From Infancy to Elderly
This study looks at the characteristics and progression of Idiopathic Interstitial Pneumopathy in both kids and adults to better understand how the condition affects them over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Sex | All |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 2 sites (Bron and 1 other locations) |
| Trial ID | NCT04238871 on ClinicalTrials.gov |
What this trial studies
This observational cohort aims to describe the phenotypic features of pediatric and adult patients diagnosed with Idiopathic Interstitial Pneumopathy (IIP/PID) and to monitor their progression over time. The study includes both prospective and retrospective data collection from patients at specialized reference centers in France. By analyzing clinical, radiological, and functional criteria, the study seeks to provide insights into the natural history of various forms of IIP/PID.
Who should consider this trial
Good fit: Ideal candidates include pediatric and adult patients exhibiting chronic respiratory insufficiency symptoms and specific radiological and functional lung abnormalities.
Not a fit: Patients with diffuse parenchymal lung diseases caused by other conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of IIP/PID, leading to improved diagnosis and management strategies for patients.
How similar studies have performed: Other observational studies have successfully characterized similar conditions, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical criteria: chronic respiratory insufficiency manifestations including dyspnea/tachypnea, cough, and cyanosis during exercise or at rest * Radiological criteria: characteristic chest High-Resolution Computed Tomography (HRCT) abnormalities including widespread ground glass or alveolar attenuation, reticulation often associated with traction bronchiectasis, and honeycombing * Functional criteria: pulmonary function test abnormalities reflecting a restrictive pattern and including: loss of lung volume, vital capacity (VC), total lung capacity (TLC); reduction in the diffusion capacity of the lung for carbon monoxide (DLCO), gas exchange abnormalities, and altered ventilatory response to exercise * Patients (parents/guardians for paediatric/patients) having given an informed consent to participate in the protocol * Patients affiliated to the "Regime National d'Assurance Maladie" Exclusion Criteria: * Patients with diffuse parenchymal lung diseases caused by drug toxicity, immunodeficiency, proliferative disorders including histiocytosis, and metabolic disorders * Patients (parents/guardians for paediatric patient) not able to approve/understand the protocol
Where this trial is running
Bron and 1 other locations
- CHU Lyon - Hôpital Louis Pradel — Bron, France (Recruiting)
- AP-HP - Hôpital Armand Trousseau — Paris, France (Recruiting)
Study contacts
- Study coordinator: Marie Chevereau
- Email: marie.chevereau@radico.fr
- Phone: + 33 1 71 73 87 94
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.